Abstract: A novel high speed, high resolution Reverse phase-HPLC method was developed for estimation of assay in Dabigatran etexilate mesylate drug substance. The separation of drug from the possible impurities was achieved on an Inertsil C8 column. Ammonium formate buffer at pH 5.5 and acetonitrile mixture was selected as a mobile phase. Flow rate and detection were kept at 1.0 mL/min and 255 nm respectively. Column and sample compartment temperatures were maintained at ambient. Sample diluent was a mixture of buffer with acetonitrile. The developed HPLC method was subjected to validation parameters; Precision, Specificity, Linearity, Robustness, Ruggedness to comply with guidelines specified by ICH. Stability indicating nature of the method was also studied by exposing the sample under various conditions like acid, base, peroxide and photo stability conditions. Using the method one can carry out quantitative estimation of assay in Dabigatran etexilate mesylate drug substance, further the same method can be adopted for determination of related substances also.

Key words: Dabigatran Etexilate Mesylate, Anticoagulant, High performance liquid chromatography, Validation, Forced degradation.

Introduction

Dabigatran etexilate mesylate is chemically Ethyl-3-[[2-[4-[2-N-hexoxy carbonyl carbamimidoyl] anilino] methyl]-1-methyl benzimidazole-5-carbonyl]-pyridin-2-ylamo] propanoate; methane sulfonic acid. The empirical formula is C\(_{56}\)H\(_{54}\)N\(_4\)O\(_{13}\)•CH\(_3\)O\(_2\)S and the molecular weight is 723.86 g/mol. Figure 1 indicated chemical structure of the molecule. Dabigatran etexilate mesylate is a yellow-white to yellow powder. A saturated solution in pure water has a solubility of 1.8 mg/mL. It is freely soluble in methanol, slightly soluble in ethanol, and sparingly soluble in isopropanol. It is sold under the brand name of Pradaxa contains 75mg, 110mg and 150mg of Dabigatran drug substance. Dabigatran is a recently developed anti thrombin anticoagulant which is used for prevention of stroke and venous embolism in patients with chronic atrial fibrillation [US FDA]. As per the literature, determination of dabigatran etexilate mesylate in pharmaceutical dosage forms may be performed by TLC [Pintu.B], spectro photometric method [Hussain Syed shahed, Harini.U and Kumar Raja Jayavarapu] and LC-MS/MS [Nouman EG] methods. LC [Nagadeep.J, Rajesh nawale and Dare.M] related substances method was proposed for bioequivalence and pharmacokinetics evaluation. Since this drug is being marketed in domestic an international market the present investigation by the author was to develop a rapid, accurate and precise RP-HPLC method for the determination of assay. The developed method was subjected to validation parameters [Snyder L.R and USFDA] such as precision, linearity, accuracy, robustness and ruggedness to prove accurate, precise and rugged method. The method was validated according to ICH requirements [ICH Q2, ICH Q1B and ICH Q3A (R2)]. Stability indicating nature of the method was demonstrated by exposing the drug to various stress conditions like acid hydrolysis, Base hydrolysis, heat and photo stability studies.

Materials and Methods

Instrumentation and Reagents

Agilent Make High performance liquid chromatography with photo diode array detector was adopted for the present study. Merck AR Grade Ammonium formate and Gradient grade acetonitrile reagents were used to prepare mobile phase. Inerttsil C8, 250 x 4.6 mm 5µm column purchased from advanced materials technology.

Chromatographic Conditions

Chromatographic separation was achieved on a Inerttsil C8, 250 x 4.6 mm 5µm Column. Mobile phase consists of 10 mM Ammonium formate buffer and HPLC grade acetonitrile. Mobile phase flow rate was kept at 1.0mL/min with a simple gradient. Gradient program was set as Time/ % of solution B: 0/50, 15/70, 15.5/50, 20/50. Column temperature was maintained at ambient and detection was carried at 255nm. Sample compartment was maintained at ambient with an
injection volume of 10\µL. Buffer with acetonitrile in the ratio of 1:1 was used for preparation of standard and test solutions.

**Preparation of Standard and Sample**
Accurately weighed and transferred 25 mg of Standard solution and test solutions in a 100 mL volumetric flask separately, dissolved and diluted to the volume with diluent. Final concentration of dabigatran in the sample and standard was 0.25 mg/mL.

**Method Validation**

**System suitability**
To ensure system suitability, a standard solution was injected on to the system and verified spectral purity of individual peaks to confirm that no co elution has been occurred. Tailing factor (T), column efficiency (N) and resolution (R) were calculated for Dabigatran.

**Specificity**
Specificity is the ability of method to measure the analyte response in the presence of its potential impurities. The specificity of the developed RP-HPLC method was demonstrated by forced degradation studies to prove stability indicating nature of the method.

**Precision**
Precision of the method was reported by injecting five replicates of standard solution consecutively under the same analytical conditions. The % RSD of individual peaks was calculated. Intermediate precision of the method also evaluated using different analyst, different day and different make of instrument in the same laboratory.

**Linearity**
Linearity for the related substances method was prepared by serially diluting the impurity stock solution to required concentration levels. The solutions were prepared at five different concentration levels ranging from 60% to 140% with respect to specification limits. The calibration curve was drawn by plotting the peak area versus its corresponding concentrations. Correlation coefficient of the calibration curve and slope were reported.

**Accuracy**
Dabigatran standard solution was prepared at three concentration levels varying from 60%, 100% and 140% of concentration. The % recovery of three levels were reported. Percentage recovery was derived based on amount of standard addition and amount of recovery in the test sample solution. % Recovery should be not less than 80% and not more than 120%.

**Robustness**
The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage.

**Results and Discussion**

**Method Development and optimization**
The objective of the development is to have more specific method to achieve the separation between all impurities from the drug substance effectively and to support routine quality check at competitive time period. The wavelength of detection was finalized at 255 nm as all the degrador and dabigatran shows maximum absorbance at selected wavelength. Resolution and peak symmetry are optimal in Inertsil C8. A simple gradient was selected to resolve all the degradants and to eliminate interference with diluent and unidentified peaks from sample.

**System Suitability Results**
The peak shape of Dabigatran drug substance was found symmetric and well separated by its degrador impurities. A typical system suitability chromatogram of sample diluent, standard solution and test solution chromatograms are shown in Figure 2(a), 2(b) and 2(c). In the optimized conditions, Dabigatran and its related substances were well resolved with a resolution of more than 2.0. The tailing factor is in the range of 1.0 - 1.2 which indicates symmetry of peaks. Theoretical plates more than 10000 show the efficiency of the column. System suitability parameters for Dabigatran drug substance are tabulated in Table 1.

![Figure 2. A typical chromatogram of Dabigatran](image-url)
Method Validation Results

Precision
System precision was performed by performing five replicates of the standard solution at specification level. The % relative standard deviation of 5 injections was within the acceptable limit. Which indicates the precision of the system to proceed for analysis. Results are tabulated in Table 2.

Table 2. System Precision Results

<table>
<thead>
<tr>
<th>System precision</th>
<th>No. of Injections</th>
<th>Peak area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>3431189</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>3429966</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3392211</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>3494455</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>3388877</td>
</tr>
<tr>
<td>AVG</td>
<td></td>
<td>3427340</td>
</tr>
<tr>
<td>STD DEV</td>
<td></td>
<td>42542.87</td>
</tr>
<tr>
<td>% RSD</td>
<td></td>
<td>1.24</td>
</tr>
</tbody>
</table>

Table 3. Linearity Results

<table>
<thead>
<tr>
<th>Linear response</th>
<th>No. of Injects</th>
<th>Conc (Ppm)</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>150.00</td>
<td>205871</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>200.00</td>
<td>2744951</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>250.00</td>
<td>3431189</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>300.00</td>
<td>4117426</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>350.00</td>
<td>4803663</td>
<td></td>
</tr>
<tr>
<td>Slope</td>
<td>13724.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y-intercept</td>
<td>0.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Correlation coe.</td>
<td>1.0000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Linearity
Linearity of the method is to establish a linear relationship of concentration against response. Solutions of dabigatran are prepared from 60% level to 140% of the specification limit. The obtained correlation coefficient was greater than 0.99. The regression statistics for dabigatran drug substance are tabulated in Table-3. Linearity plot is shown in Figure-3. The result shows that an excellent correlation between the peak response and concentration of the analyte.

Accuracy
Accuracy of the method can be determined by spiking known concentrations of standard solution. The obtained recovery value indicates the trueness of the method to estimate drug. Dabigatran standard was prepared in a concentration range varying from 60% to 140% of their respective target analyte concentrations. The Acceptance criteria for the accuracy is 80% to 120%. The obtained percentage recovery value is in the range of 96.5 % to 99.2% which declares the method accuracy. Accuracy results are reported in Table 4.

Table 4. Accuracy Results

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Accuracy Level</th>
<th>Dabigatran recovery</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60%</td>
<td>96.5%</td>
<td>80% to</td>
</tr>
<tr>
<td>2</td>
<td>100%</td>
<td>98.4%</td>
<td>120%</td>
</tr>
<tr>
<td>3</td>
<td>140%</td>
<td>99.2%</td>
<td></td>
</tr>
</tbody>
</table>

Forced degradation study
Degradation studies were performed to demonstrate stability indicating nature of the method. Dabigratn test sample was exposed to various stress conditions like heat & humidity (40°C & 70% RH for 7 days), thermal (60°C for 7 days) and photolytic conditions of fluorescent light (1.2x106 LUX hours), UV light for a total exposure of 200 W·hr/m2, acid hydrolysis (0.1N HCl 80°C for 24 Hrs), base hydrolysis (0.1N NaOH, 80°C for 24 Hrs) and oxidative stress. Testing of peak purity concludes the homogeneity.

Table 5. Forced degradation studies

<table>
<thead>
<tr>
<th>Stress condition</th>
<th>Conc. µg/mL</th>
<th>Purity angle</th>
<th>Purity Threshold</th>
<th>Mass balance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-stressed</td>
<td>250</td>
<td>0.07</td>
<td>5.21</td>
<td>100</td>
</tr>
<tr>
<td>Acid hydrolysis</td>
<td>254</td>
<td>0.01</td>
<td>2.44</td>
<td>99.2</td>
</tr>
<tr>
<td>Base hydrolysis</td>
<td>256</td>
<td>0.08</td>
<td>3.21</td>
<td>98.9</td>
</tr>
<tr>
<td>Oxidation</td>
<td>248</td>
<td>0.02</td>
<td>4.22</td>
<td>99.9</td>
</tr>
<tr>
<td>Heat and humidity</td>
<td>249</td>
<td>0.09</td>
<td>1.25</td>
<td>98.8</td>
</tr>
<tr>
<td>Photo stability</td>
<td>255</td>
<td>0.07</td>
<td>2.45</td>
<td>98.5</td>
</tr>
<tr>
<td>Dry heat</td>
<td>251</td>
<td>0.09</td>
<td>3.42</td>
<td>98.6</td>
</tr>
</tbody>
</table>

Peak obtained in all the stress conditions was homogenous and unaffected by the presence of its degradation impurities, confirming the stability indicating nature of the method. Mass balance also established to match up the sum of impurities with its assay value against reference unstressed sample. The results from forced degradation studies are summarized in Table 5.

Conclusion
A Reverse phase-HPLC method was developed for the estimation of assay in dabigatran drug substance. The developed method was subjected to method validation parameters as recommended by ICH. Stability indicating nature of the method is also established by applying forced degradation studies. The developed method was specific, precise, accurate and linear to estimate accurate amount of drug present in the sample. Degradation studies confirmed the homogeneity and free of interferences with the peak of interest. The method can be adopted to
determine the assay of drug substance in quality control labs.

References

Cite this article as:

Source of support: Nil; Conflict of interest: Nil.